Edition:
United States

Eiger BioPharmaceuticals Inc (EIGR.OQ)

EIGR.OQ on NASDAQ Stock Exchange Global Market

13.70USD
22 May 2018
Change (% chg)

$-0.95 (-6.48%)
Prev Close
$14.65
Open
$14.50
Day's High
$14.50
Day's Low
$13.45
Volume
13,524
Avg. Vol
42,199
52-wk High
$18.00
52-wk Low
$6.15

Select another date:

Wed, May 16 2018

BRIEF-Progeria Research Foundation Announces Collaboration, Supply Agreement With Eiger Biopharma

* PROGERIA RESEARCH FOUNDATION ANNOUNCES COLLABORATION AND SUPPLY AGREEMENT WITH EIGER BIOPHARMACEUTICALS Source text for Eikon: Further company coverage:

BRIEF-Eiger Announces Expanded License Agreement With Merck For Lonafarnib

* EIGER ANNOUNCES EXPANDED LICENSE AGREEMENT WITH MERCK FOR INVESTIGATIONAL CANDIDATE LONAFARNIB AND COLLABORATION WITH THE PROGERIA RESEARCH FOUNDATION (PRF) Source text for Eikon: Further company coverage:

BRIEF-Eiger Biopharmaceuticals Reports First Quarter 2018 Financial Results

* EIGER BIOPHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Eiger Biopharmaceuticals Sees Phase 3 D-Livr Trial Starting In Second Half 2018​

* EIGER BIOPHARMACEUTICALS ANNOUNCES POSITIVE GUIDANCE FOLLOWING FDA MEETING ON HEPATITIS DELTA VIRUS REGISTRATION PROGRAM

BRIEF-Eiger Biopharmaceuticals Q4 Loss Per Share $1.11

* EIGER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Eiger to abandon blood pressure drug after trial failure

Eiger BioPharmaceuticals Inc said on Tuesday it would stop development of its blood pressure drug after it failed in a mid-stage study, sending its shares plunging about 46 percent.

UPDATE 2-Eiger to abandon blood pressure drug after trial failure

* Shares slump about 46 pct in morning trading (Adds details on company's pipeline, CEO's and analyst comment, background on PAH; updates share movement)

Eiger BioPharma abandons blood pressure drug after failed study

Jan 16 Eiger BioPharmaceuticals Inc said on Tuesday it would stop testing its drug ubenimex for the treatment of pulmonary arterial hypertension, a type of high blood pressure, after the drug failed to meet the main goal in a mid-stage study.

BRIEF-Eiger Biopharma Says Phase 2 Liberty Study In Pulmonary Arterial Hypertension Did Not Meet Main Goal

* EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT

BRIEF-Eiger Biopharma Files For Mixed Shelf Of Up To $125 Mln

* EIGER BIOPHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $125 MILLION - SEC FILING Source text: (http://bit.ly/2nUkpvR) Further company coverage:

Select another date: